KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Usmani, S., Patel, K., Hari, P., Berdeja, J., Alsina, M., Vij, R., Raje, N., Leleu, X., Dhodapkar, M., Reshef, R., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Ananthakrishnan, R., Greggio, C., Favre-Kontula, L., Sternas, L., & San-Miguel, J. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140(Supplement 1), 875–877. https://doi.org/10.1182/blood-2022-162469
Authors:
Saad Z. Usmani
Krina K. Patel
Parameswaran Hari
Jesús G. Berdeja
Melissa Alsina
Ravi Vij
Noopur Raje
Xavier Leleu
Madhav V. Dhodapkar
Ran Reshef
Anna Truppel-Hartmann
Debashree Basudhar
Ethan Thompson
Xirong Zheng
Revathi Ananthakrishnan
Chiara Greggio
Linda Favre-Kontula
Lars Sternas
Jesús F. San Miguel
Affiliated Authors:
Ran Reshef
Columbia Affiliation:
Subjects:
Diagnosis and Treatment of Multiple Myeloma (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Molecular Mechanisms of Insect Resistance to Xenobiotics (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2022-162469
DOI:
10.1182/blood-2022-162469
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: